The FDA grants Priority Review status to GlaxoSmithKline’s (NYSE:GSK) marketing application for belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma (MM) in patients whose prior therapies included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.
Belantamab mafodotin is an immunoconjugate comprised of a humanized anti-B cell maturation antigen monoclonal antibody conjugated to a cytotoxic agent called auristatin F via a non-cleavable linker in-licensed from Seattle Genetics (NASDAQ:SGEN).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.